Ulcerative Proctitis and Anorectal Crohn’s Disease

  • Colin B. Peirce
  • Matthew F. KaladyEmail author


Ulcerative proctitis and anorectal Crohn’s disease often provide clinical challenges and involve multidisciplinary care including medicine and surgery. The main treatment goals are to alleviate symptoms and maintain or regain a reasonable quality of life. Advances in medications and the development of novel surgical techniques have broadened patient options and improved outcomes. This chapter reviews the medical and surgical management of ulcerative proctitis and anorectal Crohn’s disease and their respective challenges and outcomes.


Proctitis Ulcerative colitis Crohn’s disease Anorectal Perianal Fistula 



Ulcerative proctitis


Ulcerative colitis


Inflammatory bowel disease


Tumor necrosis factor




Beclomethasone dipropionate


Epithelial growth factor


Sacral nerve stimulation


Crohn’s disease


Hidradenitis suppuritiva


Examination under anesthesia


Magnetic resonance imaging






  1. 1.
    Lie MRKL, Kanis SL, Hansen BE, Jannake van der Woude C. Drug therapies for ulcerative proctitis: systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20:2157–78.PubMedCrossRefGoogle Scholar
  2. 2.
    Meucci G, Vecchi M, Astegiano M, Beretta L, Cesari P, Dizioli P, Ferraris L, Panelli MR, Prada A, Sostegni R, de Franchis R. The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Am J Gastroenterol. 2000;95:469–73.PubMedCrossRefGoogle Scholar
  3. 3.
    Moum B, Ekbom A, Vatn MH, Elgjo K. Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol. 1999;94:1564–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Satsangi J, Silverberg MS, Vermiere S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–53.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066–78.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380:1606–19.PubMedCrossRefGoogle Scholar
  7. 7.
    Thompson AI, Lees CW. Genetics of ulcerative colitis. Inflamm Bowel Dis. 2011;17:831–48.PubMedCrossRefGoogle Scholar
  8. 8.
    Garcia Rodriguez LA, Ruigomez A, Panes J. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology. 2006;130:1588–94.PubMedCrossRefGoogle Scholar
  9. 9.
    Porter CK, Tribble DR, Aliaga PA, Halvorson HA, Riddle MS. Infectious gastroenteritis and risk of developing inflammatory bowel disease. Gastroenterology. 2008;135:781–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Takeuchi K, Smale S, Premchand P, Maiden L, Sherwood R, Thjodleifsson B, Bjornsson E, Bjarnason I. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:196–202.PubMedCrossRefGoogle Scholar
  11. 11.
    Kurata JH. Dietary and other risk factors of ulcerative colitis. A case-control study in Japan. Epidemiology Group of the Research Committee of Inflammatory Bowel Disease in Japan. J Clin Gastroenterol. 1994;19:166–71.CrossRefGoogle Scholar
  12. 12.
    Neuman MG, Nanau RM. Inflammatory bowel disease: role of diet, microbiota, life style. Transl Res. 2012;160:29–44.PubMedCrossRefGoogle Scholar
  13. 13.
    Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81:1462–71.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Koutrobakis IE, Vlachonikolis IG. Appendectomy and the development of ulcerative colitis: results of a metaanalysis of published case-control studies. Am J Gastroenterol. 2000;95:171–6.CrossRefGoogle Scholar
  15. 15.
    Hart AL, Al-Hassi HO, Rigby RJ, Bell SJ, Emmanuel AV, Knight SC, Kamm MA, Stagg AJ. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology. 2005;129:50–65.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Takahashi F, Das KM. Isolation and characterization of a colonic auto-antigen specifically recognized by colon tissue-bound immunoglobulin G from idiopathic ulcerative colitis. J Clin Invest. 1985;76:311–8.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, Yang Z, Exley M, Kitani A, Blumberg RS, Mannon P, Strober W. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004;113:1490–7.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Appleyard CB, Hernandez G, Rios-Bedoya CF. Basic epidemiology of inflammatory bowel disease in Puerto Rico. Inflamm Bowel Dis. 2004;10:106–11.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Yang S, Hong WS, Min YI, Kim HY, Yoo JY, Rhee PL, Rhee JC, Chang DK, Song IS, Jung SA, et al. Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong District, Seoul, Korea, 1986-1997. J Gastorenterol Hepatol. 2000;15:1037–42.CrossRefGoogle Scholar
  20. 20.
    Molinie F, Gower-Rousseau C, Yzet T, Merle V, Grandbastien B, Marti R, Lerebours E, Dupas JL, Colombel JF, Salomez JL, et al. Opposite evaluation in incidence of Crohn’s disease and ulcerative colitis in Northern France (1988-1999). Gut. 2004;53:843–8.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol. 2006;12:6102–8.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Jess T, Frisch M, Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol. 2013;11:43–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785–94.PubMedCrossRefGoogle Scholar
  24. 24.
    Souza MH, Troncon LE, Rodrigues CM, Viana CF, Onofre PH, Monteiro RA, Passos AD, Martinelli AL, Meneghelli UG. Trends in the occurrence (1980-1999) and clinical features of Crohn’s disease and ulcerative colitis in a university hospital in southeastern Brazil. Arq Gastroenterol. 2002;39:98–105.PubMedCrossRefGoogle Scholar
  25. 25.
    Pant C, Anderson MP, Deshpande A, Grunow JE, O’Connor JA, Philpott JR, Sferra TJ. Trends in hospitalizations of children with inflammatory bowel disease within the United States from 2000 to 2009. J Investig Med. 2013;61:1036–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol. 2012;27:1266–80.PubMedCrossRefGoogle Scholar
  27. 27.
    Betteridge JD, Armbruster SP, Maydonovitch C, Veerappan GR. Inflammatory bowel disease prevalence by age, gender, race, and geographic location in the U.S. military health care population. Inflamm Bowel Dis. 2013;19:1421–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Russel MG, Dorant E, Volovics A, Brummer RJ, Pop P, Muris JW, Bos LP, Limonard CB, Stockbrugger RW. High incidence of inflammatory bowel disease in The Netherlands: results of a prospective study. The South Limburg IBD Study Group. Dis Colon Rectum. 1998;41:33–40.PubMedCrossRefGoogle Scholar
  29. 29.
    Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041–8.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Hanauer SB. Inflammatory bowel disease. N Engl J Med. 1996;334:841–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Meyers S, Janowitz HD. The “natural history” of ulcerative colitis: an analysis of the placebo response. J Clin Gastroenterol. 1989;11:33–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Regueiro MD. Diagnosis and treatment of ulcerative proctitis. J Clin Gastroenterol. 2004;38:733–40.PubMedCrossRefGoogle Scholar
  33. 33.
    Tortora A, Purchiaroni F, Scarpellini E, et al. Colitides. Eur Rev Med Pharmacol Sci. 2012;16:1795–805.PubMedGoogle Scholar
  34. 34.
    Nielsen OH, Vainer B, Rask-Madsen J. Non-IBD and noninfectious colitis. Nat Clin Pract Gastroenterol Hepatol. 2008;5:28–39.PubMedCrossRefGoogle Scholar
  35. 35.
    Hoentjen F, Rubin DT. Infectious proctitis: when to suspect it is not inflammatory bowel disease. Dig Dis Sci. 2012;57:269–73.PubMedCrossRefGoogle Scholar
  36. 36.
    Schultheiss TE, Lee WR, Hunt MA, et al. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 1997;37:3–11.PubMedCrossRefGoogle Scholar
  37. 37.
    Henson C. Chronic radiation proctitis: issues surrounding delayed bowel dysfunction post-pelvic radiotherapy and an update on medical treatment. Ther Adv Gastroenterol. 2010;3:359–65.CrossRefGoogle Scholar
  38. 38.
    Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005;61:1019–34.PubMedCrossRefGoogle Scholar
  39. 39.
    Tagkalidis PP, Tjandra JJ. Chronic radiation proctitis. ANZ J Surg. 2001;71:230–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Geraghty JM, Talbot IC. Diversion colitis: histological features in the colon and rectum after defunctioning colostomy. Gut. 1991;32:1020–3.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Whelan RL, Abramson D, Kim DS, et al. Diversion colitis. A prospective study. Surg Endosc. 1994;8:19–24.PubMedCrossRefGoogle Scholar
  42. 42.
    Orsay CP, Kim DO, Pearl RK, et al. Diversion colitis in patients scheduled for colostomy closure. Dis Colon Rectum. 1993;36:366–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Harig JM, Soergel KH, Komorowski RA, et al. Treatment of diversion colitis with short-chain-fatty acid irrigation. N Engl J Med. 1989;320:23–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Korelitz BI, Cheskin LJ, Sohn N, et al. The fate of the rectal segment after diversion of the fecal stream in Crohn’s disease: its implications for surgical management. J Clin Gastroenterol. 1985;7:37–43.PubMedCrossRefGoogle Scholar
  45. 45.
    Tas A, Koklu S, Cakal B, Yildiz F, Aktas S. Psoriatic colitis mimicking ulcerative proctitis in an elderly patient. Chin Med J. 2012;125:2080.PubMedGoogle Scholar
  46. 46.
    Tas A, Aydin YY, Koklu MAS, Mahallesi E. Hydrogen peroxide exposure mimicking ulcerative proctitis. Dig Liver Dis. 2011;43:331.PubMedCrossRefGoogle Scholar
  47. 47.
    Desoubeaux G, Gaillard J, Boree-Moreau D, Bailly E, Andres CR, Chandenier J. Gastrointestinal symptoms resembling ulcerative proctitis caused by larvae of the drone fly Eristalis tenax. Pathogens Global Health. 2014;108:158–63.PubMedCrossRefGoogle Scholar
  48. 48.
    Wu X, Liu X, Katz S, Shen B. Pathogenesis, diagnosis and management of ulcerative proctitis, chronic radiation proctopathy and diversion proctitis. Inflamm Bowel Dis. 2015;21:703–15.PubMedCrossRefGoogle Scholar
  49. 49.
    Reese GE, Constantinides VA, Simillis C, et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol. 2006;101:2410–22.PubMedCrossRefGoogle Scholar
  50. 50.
    Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci. 1993;38:1137–46.PubMedCrossRefGoogle Scholar
  51. 51.
    Ayres RC, Gillen CD, Walmsley RS, Allan RN. Progression of ulcerative proctosigmoiditis: incidence and factors influencing progression. Eur J Gastroenterol Hepatol. 1996;8:555–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Kim B, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Proximal disease extension and related predicting factors in ulcerative proctitis. Scand J Gastroenterol. 2014;49:177–83.PubMedCrossRefGoogle Scholar
  53. 53.
    Anzai H, Hata K, Kishikawa J, Ishii H, Nishikawa T, Tanaka T, Tanaka J, Kiyomatsu T, Kawai K, Nozawa H, Kazama S, Yamaguchi H, Ishihara S, Sunami E, Kitayama J, Watanabe T. Clinical pattern and progression of ulcerative colitis in the Japanese population: a retrospective study of incidence and risk factors influencing progression. Color Dis. 2015;18:O97–102.CrossRefGoogle Scholar
  54. 54.
    Henriksen M, Jahnsen J, Lygren I, Sauar J, Kjellevold O, Schulz T, Vatn MH, Moum B, IBSEN Study Group. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006;12:543–50.PubMedCrossRefGoogle Scholar
  55. 55.
    Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228–33.PubMedCrossRefGoogle Scholar
  56. 56.
    Kornbluth A, Sachar DB, The Practic Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee. Am J Gastroenterol. 2010;105:501–23.PubMedCrossRefGoogle Scholar
  57. 57.
    Lie MRKL, Kanis SL, Hansen BE, Janneke van der Woude C. Drug therapies for ulcerative proctitis: systematic review and meta-analysis. Inflamm Bowel Dis. 2014;10:2157–78.CrossRefGoogle Scholar
  58. 58.
    Cohen RD, Dalal SR. Systematic review: rectal therapies for the treatment of distal forms of ulcerative colitis. Inflamm Bowel Dis. 2015;21:1719–36.PubMedCrossRefGoogle Scholar
  59. 59.
    Loew BJ, Siegel CA. Foam preparations for the treatment of ulcerative colitis. Curr Drug Deliv. 2012;9:338–44.PubMedCrossRefGoogle Scholar
  60. 60.
    Campieri M, De Franchis R, Bianchi Porro G, et al. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol. 1990;25:663–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Campieri M, Gionchetti P, Belluzzi A, et al. Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation. A double-blind placebo controlled trial. Int J Color Dis. 1990;5:79–81.CrossRefGoogle Scholar
  62. 62.
    Pokrotnieks J, Marlicz K, Paradowski L, et al. Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther. 2000;14:1191–8.PubMedCrossRefGoogle Scholar
  63. 63.
    van Hees PAM, Bakker JH, van Tongeren JHM. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patient with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut. 1980;21:632–5.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Watanabe M, Nishino H, Sameshima Y, et al. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation – a placebo-controlled study. Aliment Pharmacol Ther. 2013;38:264–73.PubMedCrossRefGoogle Scholar
  65. 65.
    Williams CN, Haber G, Aquino JA. Double-blind, placebo-controlled evaluation of 5-asa suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-asa suppositories. Dig Dis Sci. 1987;32:71S–5S.PubMedCrossRefGoogle Scholar
  66. 66.
    Andus T, Kocjan A, Muser M, et al. Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm Bowel Dis. 2010;16:1747–56.CrossRefGoogle Scholar
  67. 67.
    Larnet M, Ptak T, Dallaire C, et al. Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. Inflamm Bowel Dis. 2005;11:625–30.CrossRefGoogle Scholar
  68. 68.
    Campieri M, Gionchetti P, Belluzzi A, et al. 5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis. J Clin Gastroenterol. 1988;10:406–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Eliakim R, Tulassay Z, Kupcinskas L, et al. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis. Aliment Pharmacol Ther. 2007;26:1237–49.PubMedCrossRefGoogle Scholar
  70. 70.
    Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;20:CD004115.Google Scholar
  71. 71.
    d’Albasio G, Paoluzi P, Campieri M, et al. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double blind placebo-controlled trial. Am J Gastroenterol. 1998;93:799–803.PubMedCrossRefGoogle Scholar
  72. 72.
    d’Arienzo A, Panarese A, d’Armiento FP, et al. 5-aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. Am J Gastroenterol. 1990;85:1079–82.PubMedGoogle Scholar
  73. 73.
    Hanauer SB, Good LI, Goodman MW, et al. Long-term use of mesalamine (Rowasa suppositories in remission maintenance in ulcerative proctitis). Am J Gastroenterol. 2000;95:1749–54.PubMedCrossRefGoogle Scholar
  74. 74.
    Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;11:CD004118.PubMedGoogle Scholar
  75. 75.
    Gionchetti P, Rizzello F, Venturi A, et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum. 1998;41:93–7.PubMedCrossRefGoogle Scholar
  76. 76.
    Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8g/day (800mg table) for the treatment of moderately active ulcerative colitis; the ASCEND II trial. Am J Gastroenterol. 2005;100:2478–85.PubMedCrossRefGoogle Scholar
  77. 77.
    Nilsson A, Danielsson A, Lofberg R, et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. Am J Gastroenterol. 1995;90:381–7.PubMedGoogle Scholar
  78. 78.
    Travis SPL, Tysk C, de Silva HJ, et al. Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut. 1994;35:1282–6.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Richter JM, Arshi NK, Oster G. Oral 5-aminosalicylate, mesalamine suppository and mesalamine enema as initial therapy for ulcerative proctitis in clinical practice with quality of care implications. Can J Gastroenterol. 2016;2016:6928710.Google Scholar
  80. 80.
    Seibold F, Fournier N, Beglinger C, Swiss IBD Cohort Study Group, et al. Topical therapy is underused in patients with ulcerative colitis. J Crohns Colitis. 2014;8:56–63.PubMedCrossRefGoogle Scholar
  81. 81.
    Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:577–85.PubMedCrossRefGoogle Scholar
  82. 82.
    Gross V, Bar-Meir S, Lavy A, The International Budesonide Study Group, et al. Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis. Aliment Pharmacol Ther. 2006;23:303–12.PubMedCrossRefGoogle Scholar
  83. 83.
    Hammond A, Andus T, Gierend M, German Budesonide Foam Study Group, et al. Controlled, open, randomized multicenter trial comparing the effects of treatment on quality of life, safety and efficacy of budesonide foam and betamethasone enemas in patients with active distal ulcerative colitis. Hepato-Gastroenterology. 2004;51:1345–9.PubMedGoogle Scholar
  84. 84.
    Hartmann F, Stein J, The BudMesa-Study Group. Clinical trial: controlled, open, randomized multicenter study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis. Aliment Pharmacol Ther. 2010;32:368–76.PubMedCrossRefGoogle Scholar
  85. 85.
    Biancone L, Gionchetti P, Del Vechhio Blanco G, et al. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liver Dis. 2007;39:329–37.PubMedCrossRefGoogle Scholar
  86. 86.
    Gionchetti P, D’Arienzo A, Rizzello F, The Italian BDP Study Group, et al. Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial. J Clin Gastroenterol. 2005;39:291–7.PubMedCrossRefGoogle Scholar
  87. 87.
    Lindgren S, Lofberg R, Bergholm L, et al. Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis. Scand J Gastroenterol. 2002;37:705–10.PubMedCrossRefGoogle Scholar
  88. 88.
    Hanauer SB, Robinson M, Pruitt R, U.S. Budesonide Enema Study Group, et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. Gastroenterology. 1998;115:525–32.PubMedCrossRefGoogle Scholar
  89. 89.
    Danielsson A, Edsbacker S, Lofberg R, et al. Pharmocokinetics of budesonide enema in patients with distal ulcerative colitis or proctitis. Aliment Pharmacol Ther. 1993;7:401–7.PubMedCrossRefGoogle Scholar
  90. 90.
    Danielsson A, Lofberg R, Persson T, et al. A steroid enema, budesonide, lacking systemic side effects for the treatment of ulcerative colitis or proctitis. Scand J Gastroenterol. 1992;27:9–12.PubMedCrossRefGoogle Scholar
  91. 91.
    Cobden I, al-Mardini H, Zaitoun A, et al. Is topical therapy necessary in acute distal colitis? Double-blind comparison of high-dose oral mesalazine versus steroid enemas in the treatment of active distal ulcerative colitis. Aliment Pharmacol Ther. 1991;5:513–22.PubMedCrossRefGoogle Scholar
  92. 92.
    Mulder CJJ, Fockns P, Meijer JWR, van der Heide H, Wiltink EHH, Tytgat GNJ. Beclomethasone dipropionate (3mg) versus 5-aminosalicylic acid (2g) versus the combination of both (3mg/2g) as retention enemas in active ulcerative colitis. Eur J Gastroenterol Hepatol. 1996;8:549–53.PubMedCrossRefGoogle Scholar
  93. 93.
    Guslandi M, Giollo P, Testoni PA. A combination of rectal beclomethasone dipropionate and mesalazine in ulcerative proctitis. Scand J Gastroenterol. 2008;43:639–40.PubMedCrossRefGoogle Scholar
  94. 94.
    Gecse KB, Lakatos PL. Ulcerative proctitis: an update on the pharmacotherapy and management. Expert Opin Pharmacother. 2014;15:1565–73.PubMedCrossRefGoogle Scholar
  95. 95.
    Bitton A. Medical management of ulcerative proctitis, proctosigmoiditis, and left-sided colitis. Semin Gastrointest Dis. 2001;12:263–74.PubMedGoogle Scholar
  96. 96.
    Love MA, Rubin PH, Chapman ML, Present DH. 6-mercaptopurine is effective in intractable proctosigmoiditis. Gastroenterology. 1995;100:A832.Google Scholar
  97. 97.
    Sandborn WJ, Tremaine WJ, Schroeder KW, et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology. 1994;106:1429–35.PubMedCrossRefGoogle Scholar
  98. 98.
    Ardizzone S, Petrillo M, Antonacci CM, Bianchi Porro G. Sucralfate and hydrocortisone enemas in the treatment of active ulcerative proctitis – a randomized single-blind comparative study. Aliment Pharmacol Ther. 1996;10:957–60.PubMedCrossRefGoogle Scholar
  99. 99.
    Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76.PubMedCrossRefGoogle Scholar
  100. 100.
    Bouguen G, Roblin X, Bourreille A, et al. Infliximab for refractory ulcerative proctitis. Aliment Pharmacol Ther. 2010;31:1178–85.PubMedCrossRefGoogle Scholar
  101. 101.
    Molnar T, Farkas K, Nagy F, et al. Topically administered infliximab can work in ulcerative proctitis despite the ineffectiveness of intravenous induction therapy. Am J Gastroenterol. 2009;104:1857–8.PubMedCrossRefGoogle Scholar
  102. 102.
    Lawrance IC, Copeland TS. Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Aliment Pharmacol Ther. 2008;28:1214–20.PubMedCrossRefGoogle Scholar
  103. 103.
    van Dieren JM, van Bodegraven AA, Kuipers EJ, et al. Local application of tacrolimus in distal colitis: feasible and safe. Inflamm Bowel Dis. 2009;15:193–8.PubMedCrossRefGoogle Scholar
  104. 104.
    Schmidt KJ, Herrlinger KR, Emmrich J, et al. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis-experience in 130 patients. Aliment Pharmacol Ther. 2013;37:129–36.PubMedCrossRefGoogle Scholar
  105. 105.
    Makiyama K, Takeshima F, Hamamoto T. Efficacy of rebamipide enemas in distal ulcerative colitis and proctitis: a prospective study report. Dig Dis Sci. 2005;50:2323–9.PubMedCrossRefGoogle Scholar
  106. 106.
    Furuta R, Ando T, Watanabe O, Maeda O, Ishiguro K, Ina K, Kusugami K, Goto H. Rebamipide enema therapy as a treatment for patients with active distal ulcerative colitis. J Gastroenterol Hepatol. 2007;22:261–7.PubMedCrossRefGoogle Scholar
  107. 107.
    Sinha A, Nightingale J, West KP, et al. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med. 2003;349:350–7.PubMedCrossRefGoogle Scholar
  108. 108.
    Kono T, Nomura M, Kasai S, et al. Effect of escabet sodium enema on mildly to moderately active ulcerative proctosigmoiditis: an open-label study. Am J Gastroenterol. 2001;96:793–7.PubMedCrossRefGoogle Scholar
  109. 109.
    Arlander E, Ost A, Stahlberg D, et al. Ropivacaine gel in active distal ulcerative colitis and proctitis – a pharmacokinetic and exploratory clinical study. Aliment Pharmacol Ther. 1996;10:73–81.PubMedCrossRefGoogle Scholar
  110. 110.
    Ng SC, Lam YT, Tsoi KK, et al. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:854–63.PubMedCrossRefPubMedCentralGoogle Scholar
  111. 111.
    Fukunaga K, Ohda Y, Hida N, et al. Placebo controlled evaluation of Xilei San, a herbal preparation in patients with intractable ulcerative proctitis. J Gastroenterol Hepatol. 2012;27:1808–15.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Zhang F, Li Y, Xu F, Chu Y, Zhao W. Comparison of Xilei-san, a Chinese herbal medicine, and dexamethasone in mild/moderate ulcerative proctitis: a double-blind randomized clinical trial. J Altern Complement Med. 2013;19:838–42.PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Actis GC, Rosina F, Pellicano R. A case of appendectomy as main therapeutic intervention for complex co-morbid ulcerative colitis. Int J Color Dis. 2015;30:1747–8.CrossRefGoogle Scholar
  114. 114.
    Bolin TD, Wong S, Crouch R, Engelman JL, Riordan SM. Appendicectomy as a therapy for ulcerative proctitis. Am J Gastroenterol. 2009;104:2476–82.PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    Shen B. Diagnosis and management of postoperative ileal pouch disorders. Clin Colon Rectal Surg. 2010;23:259–68.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Kariv R, Remzi FH, Lian L, et al. Preoperative colorectal neoplasia increases risk for pouch neoplasia in patients with restorative proctocolectomy. Gastroenterology. 2010;139:806–12.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Shen B, Lashner BA, Bennett AE, et al. Treatment of rectal cuff inflammation (cuffitis) in patients with ulcerative colitis following restorative proctocolectomy and ileal pouch-anal anastomosis. Am J Gastroenterol. 2004;99:1527–31.PubMedCrossRefPubMedCentralGoogle Scholar
  118. 118.
    Wu B, Lian L, Li Y, Remzi FH, Liu X, Kiran RP, Shen B. Clinical course of cuffitis in ulcerative colitis patients with restorative proctocolectomy and ileal pouch-anal anastomoses. Inflamm Bowel Dis. 2013;19:404–10.PubMedCrossRefPubMedCentralGoogle Scholar
  119. 119.
    Economou M, Pappas G. New global map of Crohn’s disease: genetic, environmental, and socioeconomic correlations. Inflamm Bowel Dis. 2008;14:709–20.PubMedCrossRefPubMedCentralGoogle Scholar
  120. 120.
    Loftus EV Jr, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Crohn’s disease in Olmsted County, Minneosta, 1940-1993: incidence, prevalence, and survival. Gastroenterology. 1998;114:1161–8.PubMedCrossRefPubMedCentralGoogle Scholar
  121. 121.
    Kappelman MD, Rifas-Shiman SL, Kleinman K, Ollendorf D, Bousvaros A, Grand RJ, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424–9.PubMedCrossRefPubMedCentralGoogle Scholar
  122. 122.
    Binder V. Epidemiology of IBD during the twentieth century: an integrated view. Best Pract Res Clin Gastroenterol. 2004;18:463–79.PubMedCrossRefPubMedCentralGoogle Scholar
  123. 123.
    Hellers G, Bergstrand O, Ewerth S, Holmstrom B. Occurrence and outcome after primary treatment of anal fistulae in Crohn’s disease. Gut. 1980;21:525–7.PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–24.PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Swidsinski A, Loening-Baucke V, Herber A. Mucosal flora in Crohn’s disease and ulcerative colitis – an overview. J Physiol Pharmacol. 2009;60(suppl 6):61–71.PubMedPubMedCentralGoogle Scholar
  126. 126.
    Gersemann M, Wehkamp J, Stange EF. Innate immune dysfunction in inflammatory bowel disease. J Intern Med. 2012;271:421–8.PubMedCrossRefPubMedCentralGoogle Scholar
  127. 127.
    Rutgeerts P, Goboes K, Peeters M, Hiele M, Penninckx F, Aerts R, et al. Effect of fecal diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet. 1991;338:771–4.PubMedCrossRefPubMedCentralGoogle Scholar
  128. 128.
    Ekbom A, Montgomery SM. Environmental risk factors (excluding tobacco and microorganisms): critical analysis of old and new hypotheses. Best Pract Res Clin Gastroenterol. 2004;18:497–508.PubMedCrossRefPubMedCentralGoogle Scholar
  129. 129.
    Jantchou P, Monnet E, Carbonnel F. Environmental risk factors in Crohn’s disease and ulcerative colitis (excluding tobacco and appendicectomy). Gastroenterol Clin Biol. 2006;30:859–67.PubMedCrossRefPubMedCentralGoogle Scholar
  130. 130.
    Melum E, Franke A, Karlsen TH. Genome-wide association studies – a summary for the clinical gastroenterologist. World J Gastroenterol. 2009;15:5377–96.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40:955–62.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Brochard C, Siproudhis L, Wallenhorst T, Cuen D, d’Halluin PN, Garros A, Bretagne JF, Bouguen G. Anorecatl stricture in 102 patients with Crohn’s disease: natural history in the era of biologics. Aliment Pharmacol Ther. 2014;30:796–803.CrossRefGoogle Scholar
  133. 133.
    Church JM, Fazio VW, Lavery IC, Oakley JR, Milsom JW. The differential diagnosis and comorbidity of hidradenitis suppurativa and perianal Crohn’s disease. Int J Color Dis. 1993;8:117–9.CrossRefGoogle Scholar
  134. 134.
    Schwartz DA, Wiersema MJ, Dudiak KM, et al. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn’s perianal fitulas. Gastroenterology. 2001;121:1064–72.PubMedCrossRefPubMedCentralGoogle Scholar
  135. 135.
    Schaefer O, Lohrmann C, Langer M. Assessment of anal fistulas with high-resolution subtraction MR-fistulography: comparison with surgical findings. J Magn Reson Imaging. 2004;19:91–8.PubMedCrossRefPubMedCentralGoogle Scholar
  136. 136.
    Beets-Tan RG, Beets GL, van der Hoop AG, et al. Preoperative MR imaging of anal fistulas: does it really help the surgeon? Radiology. 2001;218:75–84.PubMedCrossRefPubMedCentralGoogle Scholar
  137. 137.
    Crohn BB, Ginzberg L, Oppenheimer GD. Regional ileitis: a pathologic and clinical entity. JAMA. 1932;99:1323.CrossRefGoogle Scholar
  138. 138.
    Colles A. Practical observations upon certain diseases of intestines, colon and rectum. Dublin Hosp Rep. 1830;5:131.Google Scholar
  139. 139.
    Penner A, Crohn BB. Perianal fistulae as a complication of regional ileitis. Ann Surg. 1938;108:867–73.PubMedPubMedCentralCrossRefGoogle Scholar
  140. 140.
    McClane SJ, Rombeau JL. Anorectal Crohn’s disease. Surg Clin North Am. 2001;81:169–83.PubMedCrossRefPubMedCentralGoogle Scholar
  141. 141.
    Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB, American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn’s disease. Gastroenterology. 2003;125:1508–30.PubMedCrossRefPubMedCentralGoogle Scholar
  142. 142.
    Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002;1222:875–80.CrossRefGoogle Scholar
  143. 143.
    Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis. 2002;8:244–50.PubMedCrossRefPubMedCentralGoogle Scholar
  144. 144.
    Roberts PL, Schoetz DJ Jr, Pricolo R, Veidenheimer MC. Clinical course of Crohn’s disease in older patients. A retrospective study. Dis Colon Rectum. 1990;33:458–62.PubMedCrossRefPubMedCentralGoogle Scholar
  145. 145.
    American Gastroenterological Association Clinical Practice Committee. American Gastroenterological Association medical position statement: perianal Crohn’s disease. Gastroenterology. 2003;125:1503–7.CrossRefGoogle Scholar
  146. 146.
    Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn’s disease. Gastroenterology. 2006;130:650–6.PubMedCrossRefPubMedCentralGoogle Scholar
  147. 147.
    Rankin GB, Watts HD, Melnyk CS, Kelley ML Jr. National Cooperative Crohn’s Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology. 1979;77:914–20.PubMedPubMedCentralGoogle Scholar
  148. 148.
    Gelbmann CM, Rogler G, Gross V, et al. Prior bowel resections, perianal disease, and a high initial Crohn’s disease activity index are associated with corticosteroid resistance in active Crohn’s disease. Am J Gastroenterol. 2002;97:1438–45.PubMedCrossRefPubMedCentralGoogle Scholar
  149. 149.
    Neilsen OH, Rogler G, Hahnloser D, Thomsen O. Diagnosis and management of fistulizing Crohn’s disease. Nat Clin Prac Gastroenterol Hepatol. 2009;6:92–106.CrossRefGoogle Scholar
  150. 150.
    Sparberg M, Kirnser JB. Long term corticosteroid therapy for regional enteritis: an analysis of 58 courses in 54 patients. Am J Dig Dis. 1966;11:865–80.PubMedCrossRefPubMedCentralGoogle Scholar
  151. 151.
    Vavricka SR, Rogler G. Fistula treatment: the unresolved challenge. Dig Dis. 2010;28:556–64.PubMedCrossRefPubMedCentralGoogle Scholar
  152. 152.
    Jakobovits J, Schuster MM. Metronidazole therapy for Crohn’s disease and associated fistulae. Am J Gastroenterol. 1984;79:533–40.PubMedPubMedCentralGoogle Scholar
  153. 153.
    Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perianal Crohn’s disease: a follow-up study. Gastroenterology. 1982;83:383–7.PubMedPubMedCentralGoogle Scholar
  154. 154.
    Turunen U, Farkkila M, Seppala K. Long-term treatment of peri-anal or fistulous Crohn’s disease with ciprofloxacin. Scand J Gastroenterol. 1989;24:144.Google Scholar
  155. 155.
    Wolf J. Ciprofloxacin may be useful in Crohn’s disease. Gastroenterology. 1990;98:A212.Google Scholar
  156. 156.
    Solomon M, McLeod R, et al. Combination ciprofloxacin and metronidazole in severe perianal Crohn’s disease. Can J Gastroenterol. 1993;7:571–3.CrossRefGoogle Scholar
  157. 157.
    Thia KT, Mahaevan U, Feagan BG, Wong C, Cockeram A, Bitton A, Bernstein CN, Sandborn WJ. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn’s disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009;15:17–24.PubMedCrossRefPubMedCentralGoogle Scholar
  158. 158.
    Bressler B, Sands BE. Review article: medical therapy for fistulizing Crohn’s disease. Aliment Pharmacol Ther. 2006;24:1283–93.PubMedCrossRefPubMedCentralGoogle Scholar
  159. 159.
    Bar F, Sina C, Fellerman K. Thiopurines in inflammatory bowel disease revisited. World J Gastroenterol. 2013;19:1699–706.PubMedPubMedCentralCrossRefGoogle Scholar
  160. 160.
    Lecomte T. Predictive factors of response of perianal Crohn’s disease to azathioprine and 6-mercaptopurine. Dis Colon Rectum. 2003;46:1469–147.PubMedCrossRefPubMedCentralGoogle Scholar
  161. 161.
    Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn’s disease: a meta-analysis. Ann Intern Med. 1995;123:132–42.PubMedCrossRefPubMedCentralGoogle Scholar
  162. 162.
    Present DH, Korelitz BI, Wisch N, Glass JL, et al. Treatment of Crohn’s disease with 6-mercaptopurine: a long-term, randomized, double blind study. N Engl J Med. 1980;302:981–7.PubMedCrossRefPubMedCentralGoogle Scholar
  163. 163.
    Dejaco C, Harrer M, Waldhoer T, et al. Antiobiotics and azathioprine for the treatment of perianal fistulas in Crohn’s disease. Aliment Pharmacol Ther. 2003;18:1113–20.PubMedCrossRefPubMedCentralGoogle Scholar
  164. 164.
    Topstad DR, Panaccione R, et al. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fitsulizing anorectal crohns disease: a single center experience. Dis Colon Rectum. 2003;46:577–83.PubMedCrossRefPubMedCentralGoogle Scholar
  165. 165.
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–405.PubMedCrossRefPubMedCentralGoogle Scholar
  166. 166.
    Sands B, Van Deventer S, Bernstein C. Long-term treatment of fistulizing Crohn’s disease: response to infliximab in ACCENT II trials through 54 weeks. Gastroenterology. 2002;122:A81.Google Scholar
  167. 167.
    Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323–33.PubMedCrossRefPubMedCentralGoogle Scholar
  168. 168.
    Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut. 2009;58:940–8.PubMedPubMedCentralCrossRefGoogle Scholar
  169. 169.
    Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357:228–38.PubMedCrossRefPubMedCentralGoogle Scholar
  170. 170.
    Schreiber S, Lawrance IC, Thomsen OO, et al. Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease – subgroup results from a placebo-controlled study. Aliment Pharmacol Ther. 2011;33:185–19.PubMedCrossRefPubMedCentralGoogle Scholar
  171. 171.
    Pikarsky AJ, Gervaz P, Wexner SD. Perianal Crohn disease: a new scoring system to evaluate and predict outcome of surgical intervention. Arch Surg. 2002;137(7):774–7.Google Scholar
  172. 172.
    Cracco N, Zinicola R. Is haemorrhoidectomy in inflammatory bowel disease harmful? An old dogma re-examined. Color Dis. 2014;16:516–9.CrossRefGoogle Scholar
  173. 173.
    Fleshner PR, Schoetz DJ Jr, Roberts PL, et al. Anal fissure in Crohn’s disease: a plea for aggressive management. Dis Colon Rectum. 1995;38:1137–43.PubMedCrossRefPubMedCentralGoogle Scholar
  174. 174.
    Buchmann P, Keighley MR, Allan RN, et al. Natural history of perianal Crohn’s disease. Ten year follow-up: a plea for conservatism. Am J Surg. 1980;140:642–4.PubMedCrossRefPubMedCentralGoogle Scholar
  175. 175.
    Bergstrand O, Ewerth S, Hellers G, et al. Outcome following treatment of anal fistulae in Crohn’s disease. Acta Chir Scand Suppl. 1980;500:43–4.PubMedPubMedCentralGoogle Scholar
  176. 176.
    Makowiec F, Jehle EC, Becker HD, et al. Perianal abscess in Crohn’s disease. Dis Colon Rectum. 1997;40:443–340.PubMedCrossRefGoogle Scholar
  177. 177.
    Pascua M, Su C, Lweis JD, Brensinger C, Lichtenstein GR. Meta-analysis: factors predicting post-operative recurrence with placebo therapy in patients with Crohn’s disease. Aliment Pharmacol Ther. 2008;28:545–56.PubMedCrossRefGoogle Scholar
  178. 178.
    Sangwan YP, Schoetz DJ Jr, Murray JJ, Roberts PL, Coller JA. Perianal Crohn’s disease. Results of local surgical treatment. Dis Colon Rectum. 1996;39:529–35.PubMedCrossRefGoogle Scholar
  179. 179.
    Faucheron JL, Saint-Marc O, Guiber L, Parc R. Long-term seton drainage for high anal fistulas in Crohn’s disease – a sphincter-saving operation? Dis Colon Rectum. 1996;39:208–11.PubMedCrossRefGoogle Scholar
  180. 180.
    Thornton M, Solomon MJ. Long-term indwelling seton for complex anal fistulas in Crohn’s disease. Dis Colon Rectum. 2005;48:459–63.PubMedCrossRefGoogle Scholar
  181. 181.
    Buchanan GN, Owen HA, Torkington J, Lunniss PJ, Nicholls RJ, Cohen CR. Long-term outcome following loose-seton technique for external sphincter preservation in complex anal fistula. Br J Surg. 2004;91:476–80.PubMedCrossRefGoogle Scholar
  182. 182.
    Eitan A, Koliada M, Bickel A. The use of the loose seton technique as a definitive treatment for recurrent and persistent high trans-sphincteric anal fistulas: a long-term outcome. J Gastrointest Surg. 2009;13:1116–9.PubMedCrossRefGoogle Scholar
  183. 183.
    Halme L, SAinio AP. Factors related to frequency, type, and outcome of anal fistulas in Crohn’s disease. Dis Colon Rectum. 1995;38:55–9.PubMedCrossRefGoogle Scholar
  184. 184.
    Levin DH, Surrell J, Mazier WP. Surgical treatment of anorectal fistula in pateints with Crohn’s disease. Surg Gynecol Obstet. 1989;169:133–6.Google Scholar
  185. 185.
    Fuhrman GM, Larach SW. Experience with perirectal fistulas in patients with Crohn’s disease. Dis Colon Rectum. 1989;32:847–8.PubMedCrossRefGoogle Scholar
  186. 186.
    Sonoda T, Hull T, Piedmonte MR, Fazio VW. Outcomes of primary repair of anorectal and rectovaginal fistulas using the endorectal advancement flap. Dis Colon Rectum. 2002;45:1622–8.PubMedCrossRefGoogle Scholar
  187. 187.
    Mizrahi N, Wexner SD, Zmora O, Da Silva G, Efron J, Weiss EG, Vernava AM, Nogueras JJ. Endorectal advancement flap: are there predictors of failure? Dis Colon Rectum. 2002;45:1616–21.PubMedCrossRefGoogle Scholar
  188. 188.
    Jarrar A, Church J. Advancement flap repair: a good option for complex anorectal fistulas. Dis Colon Rectum. 2011;54:1537–41.PubMedCrossRefGoogle Scholar
  189. 189.
    Soltani A, Kaiser AM. Endorectal advancement flap for cryptoglandular or Crohn’s fistula-in-ano. Dis Colon Rectum. 2010;53:486–95.PubMedCrossRefGoogle Scholar
  190. 190.
    Rojanasakul A. LIFT procedure: a simplified technique for fistula-in-ano. Tech Coloproctol. 2009;13:237–40.PubMedCrossRefGoogle Scholar
  191. 191.
    Bleier JI, Moloo H, Goldberg SM. Ligation of the intersphincteric fistula tract: an effective new technique for complex fistulas. Dis Colon Rectum. 2010;53:43–6.PubMedCrossRefGoogle Scholar
  192. 192.
    Ooi K, Skinner I, Croxford M, Faragher I, McLaughlin S. Managing fistula-in-ano with ligation of the intersphincteric fistula tract procedure: the Western Hospital experience. Color Dis. 2012;14:599–603.CrossRefGoogle Scholar
  193. 193.
    Shanwani A, Nor AM, Amri N. Ligation of the intersphincteric fistula tract (LIFT): a sphincter-saving technique for fistula-in-ano. Dis Colon Rectum. 2010;53:39–42.PubMedCrossRefGoogle Scholar
  194. 194.
    Gingold DS, Murrell ZA, Fleshner PR. A prospective evaluation of the ligation of the intersphincteric tract procedure for complex anal fistula in patients with Crohn’s disease. Ann Surg. 2014;260:1057–61.PubMedCrossRefGoogle Scholar
  195. 195.
    O’Riordan JM, Datta I, Johnston C, Baxter NN. A systematic review of the anal fistula plug for patients with Crohn’s and non-Crohn’s related fistula-in-ano. Dis Colon Rectum. 2012;55:351–8.PubMedCrossRefGoogle Scholar
  196. 196.
    Garg P, Song J, Bhatia A, Kalia H, Menon GR. The efficacy of anal fistula plug in fistula-in-ano: a systematic review. Color Dis. 2010;12:965–70.CrossRefGoogle Scholar
  197. 197.
    Gonsalves S, Sagar P, Lengyel J, Morrison C, Dunham R. Assessment of the efficacy of the rectovaginal button fistula plug for the treatment of ileal pouch-vaginal and rectovaginal fistulas. Dis Colon Rectum. 2009;52:1877–81.PubMedCrossRefGoogle Scholar
  198. 198.
    Ellis CN. Outcomes after repair of rectovaginal fistulas using bioprosthetics. Dis Colon Rectum. 2008;51:1084–8.PubMedCrossRefGoogle Scholar
  199. 199.
    Cintron JR, Park JJ, Orsay CP, Pearl RK, Nelson RL, Abcarian H. Repair of fistulas-in-ano using autologous fibrin tissue adhesive. Dis Colon Rectum. 1999;42:607–13.PubMedCrossRefGoogle Scholar
  200. 200.
    Cintron JR, Park JJ, Orsay CP, et al. Repair of fistulas-in-ano using fibrin adhesive: long-term follow-up. Dis Colon Rectum. 2000;43:944–9.PubMedCrossRefGoogle Scholar
  201. 201.
    Park JJ, Cintron JR, Orsay CP, et al. Repair of chronic anorectal fistulae using commercial fibrin sealant. Arch Surg. 2000;135:166–9.PubMedCrossRefGoogle Scholar
  202. 202.
    Swinscoe MT, Ventakasubramaniam AK, Jayne DG. Fibrin glue for fistula-in-ano: the evidence reviewed. Tech Coloproctol. 2005;9:89–94.PubMedCrossRefGoogle Scholar
  203. 203.
    Zmora O, Neufeld D, Ziv Y, et al. Prospective, multicenter evaluation of highly concentrated fibrin glue in the treatment of complex cryptogenic perianal fistulas. Dis Colon Rectum. 2005;48:2167–72.PubMedCrossRefGoogle Scholar
  204. 204.
    Sehgal R, Koltun WA. Fibrin glue for the treatment of perianal fistulous Crohn’s disease. Gastroenterology. 2010;138:2216–9.PubMedCrossRefGoogle Scholar
  205. 205.
    Grimaud JC, Munoz-Bongrand N, Siproudhis L, Abramowitz L, Senejoux A, Vitton V, Gambiez L, Flourie B, Hebuterne X, Louis E, Coffin B, De Parades V, Savoye G, Soule JC, Bouhnik Y, Colombel JF, Contou JF, Francois Y, Mary JY, Lemann M. Groupd d’Etude therapeutique des affections inflammatories du tube digestif. Gastroenterology. 2010;138:2275–81.PubMedCrossRefGoogle Scholar
  206. 206.
    Loungnarath R, Dietz DW, Mutch MG, Birnbaum EH, Kodner IJ, Fleshner JW. Fibrin glue treatment of complex anal fistulas has low success rate. Dis Colon Rectum. 2004;47:432–6.PubMedCrossRefGoogle Scholar
  207. 207.
    Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, Danese S, ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388(10051):1281–90. Epub 2016 Jul 29.CrossRefGoogle Scholar
  208. 208.
    Galandiuk S, Kimberling J, Al-Mishlab TG, Stromberg AJ. Perianal Crohn’s disease: predictors of need for permanent diversion. Ann Surg. 2005;241:796–801. discussion 801-802PubMedPubMedCentralCrossRefGoogle Scholar
  209. 209.
    Yamamoto T, Allan RN, Keighley MR. Effect of fecal diversion alone on perianal Crohn’s disease. World J Surg. 2000;24:1258–62. discussion 1262-1263PubMedCrossRefGoogle Scholar
  210. 210.
    Figg RE, Church JM. Perineal Crohn’s disease: an indicator of poor prognosis and potential proctectomy. Dis Colon Rectum. 2009;52:646–50.PubMedCrossRefGoogle Scholar
  211. 211.
    Yamamoto T, Bain IM, Allan RN, Keighley MR. Persistent perineal sinus after proctocolectomy for Crohn’s disease. Dis Colon Rectum. 1999;42:96–101.PubMedCrossRefGoogle Scholar
  212. 212.
    Causey MW, Nelson D, Johnson EK, Maykel J, Davis B, Rivadeneira DE, Champagne D, Steele SR. An NSQIP evaluation of practice patterns and outcomes following surgery for anorectal abscess and fistula in patients with and without Crohn’s disease. Gastroenterol Rep. 2013;1:58–63.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of SurgeryUniversity of Limerick Hospitals GroupLimerickIreland
  2. 2.Department of Colorectal SurgeryDigestive Disease and Surgery Institute, Cleveland ClinicClevelandUSA

Personalised recommendations